CoChat
Sign Up
Cited by 53Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersLung Cancer Research Studies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets

Open access
Taguchi, Ayumu, Taylor, Allen D., Rodriguez, Jaime, Çeliktaş, Müge, Liu, Hui, Ma, Xiaotu, Zhang, Qing, Wong, Chee-Hong, Chin, Alice, Girard, Luc, Behrens, Carmen, Lam, Wan L., Lam, Stephen, Minna, John D., Wistuba, Ignacio I., Gazdar, Adi F., Hanash, Samir M.·2014·Cancer Research
DOI 10.1158/0008-5472.can-13-3725PMC PMC4398029

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Cancer/testis (CT) antigens are potential immunotherapeutic targets in cancer. However, the expression of particular antigens is limited to a subset of tumors of a given type. Thus, there is a need to identify antigens with complementary expression patterns for effective therapeutic intervention. In this study, we searched for genes that were distinctly expressed at a higher level in lung tumor tissue and the testes compared with other nontumor tissues and identified members of the VCX/Y gene family as novel CT antigens. VCX3A, a member of the VCX/Y gene family, was expressed at the protein level in approximately 20% of lung adenocarcinomas and 35% of squamous cell carcinomas, but not expressed in normal lung tissues. Among CT antigens with concordant mRNA and protein expression levels, four CT antigens, XAGE1, VCX, IL13RA2, and SYCE1, were expressed, alone or in combination, in about 80% of lung adenocarcinoma tumors. The CT antigen VCX/Y gene family broadens the spectrum of CT antigens expressed in lung adenocarcinomas for clinical applications. Cancer Res; 74(17); 4694–705. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-3725

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. Schlom, 2012, Therapeutic cancer vaccines: current status and moving forward, J Natl Cancer Inst, 104, 599, 10.1093/jnci/djs033 · DOI
  2. Dougan, 2009, Immune therapy for cancer, Annu Rev Immunol, 27, 83, 10.1146/annurev.immunol.021908.132544 · DOI
  3. Simpson, 2005, Cancer/testis antigens, gametogenesis and cancer, Nat Rev Cancer, 5, 615, 10.1038/nrc1669 · DOI
  4. Suri, 2006, Cancer testis antigens–their importance in immunotherapy and in the early detection of cancer, Expert Opin Biol Ther, 6, 379, 10.1517/14712598.6.4.379 · DOI
  5. Chiriva-Internati, 2012, Cancer testis antigens: a novel target in lung cancer, Int Rev Immunol, 31, 321, 10.3109/08830185.2012.723512 · DOI
  6. Fratta, 2011, The biology of cancer testis antigens: putative function, regulation and therapeutic potential, Mol Oncol, 5, 164, 10.1016/j.molonc.2011.02.001 · DOI
  7. Vansteenkiste, 2013, Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results, J Clin Oncol, 31, 2396, 10.1200/JCO.2012.43.7103 · DOI
  8. Kakimi, 2011, A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen, Int J Cancer, 129, 2836, 10.1002/ijc.25955 · DOI
  9. Hansen, 2008, A shared promoter region suggests a common ancestor for the human VCX/Y, SPANX, and CSAG gene families and the murine CYPT family, Mol Reprod Dev, 75, 219, 10.1002/mrd.20651 · DOI
  10. Jiao, 2006, Identification of an mRNA-decapping regulator implicated in X-linked mental retardation, Mol Cell, 24, 713, 10.1016/j.molcel.2006.10.013 · DOI
  11. Li, 2011, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome, BMC Bioinformatics, 12, 323, 10.1186/1471-2105-12-323 · DOI · Paper page
  12. Selamat, 2012, Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression, Genome Res, 22, 1197, 10.1101/gr.132662.111 · DOI
  13. Thu, 2012, Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability, PLoS ONE, 7, e33003, 10.1371/journal.pone.0033003 · DOI
  14. Taguchi, 2011, Lung cancer signatures in plasma based on proteome profiling of mouse tumor models, Cancer Cell, 20, 289, 10.1016/j.ccr.2011.08.007 · DOI · Paper page
  15. Ong, 2006, A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC), Nat Protoc, 1, 2650, 10.1038/nprot.2006.427 · DOI
  16. Faca, 2007, Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes, J Proteome Res, 6, 3558, 10.1021/pr070233q · DOI
  17. Faca, 2008, Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains, PLoS ONE, 3, e2425, 10.1371/journal.pone.0002425 · DOI
  18. Sun, 2009, HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors, Clin Cancer Res, 15, 4829, 10.1158/1078-0432.CCR-08-2921 · DOI
  19. Ladd, 2013, Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women, Cancer Res, 73, 1502, 10.1158/0008-5472.CAN-12-2560 · DOI
  20. Ladd, 2012, Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women, Cancer Prev Res, 5, 655, 10.1158/1940-6207.CAPR-11-0412 · DOI
  21. Su, 2004, A gene atlas of the mouse and human protein-encoding transcriptomes, Proc Natl Acad Sci U S A, 101, 6062, 10.1073/pnas.0400782101 · DOI · Paper page
  22. Hofmann, 2008, Genome-wide analysis of cancer/testis gene expression, Proc Natl Acad Sci U S A, 105, 20422, 10.1073/pnas.0810777105 · DOI
  23. Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res, 37, D816, 10.1093/nar/gkn673 · DOI
  24. Parker, 1994, Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains, J Immunol, 152, 163, 10.4049/jimmunol.152.1.163 · DOI
  25. Rammensee, 1999, SYFPEITHI: database for MHC ligands and peptide motifs, Immunogenetics, 50, 213, 10.1007/s002510050595 · DOI
  26. Gonzalez-Galarza, 2011, Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations, Nucleic Acids Res, 39, D913, 10.1093/nar/gkq1128 · DOI
  27. Fukami, 2000, A member of a gene family on Xp22.3, VCX-A, is deleted in patients with X-linked nonspecific mental retardation, Am J Hum Genet, 67, 563, 10.1086/303047 · DOI
  28. Lahn, 2000, A human sex-chromosomal gene family expressed in male germ cells and encoding variably charged proteins, Hum Mol Genet, 9, 311, 10.1093/hmg/9.2.311 · DOI
  29. Fukutomi, 2007, Identification of methylation-silenced genes in colorectal cancer cell lines: genomic screening using oligonucleotide arrays, Scand J Gastroenterol, 42, 1486, 10.1080/00365520701491173 · DOI
  30. Zou, 2003, Expression and localization of VCX/Y proteins and their possible involvement in regulation of ribosome assembly during spermatogenesis, Cell Res, 13, 171, 10.1038/sj.cr.7290161 · DOI
  31. Nakagawa, 2005, XAGE-1 expression in non-small cell lung cancer and antibody response in patients, Clin Cancer Res, 11, 5496, 10.1158/1078-0432.CCR-05-0216 · DOI
  32. Sato, 2007, Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors, Cancer Immun, 7, 5
  33. Ohue, 2012, Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients, Int J Cancer, 131, E649, 10.1002/ijc.27359 · DOI
  34. Nakashima, 2012, IL-13 receptor-directed cancer vaccines and immunotherapy, Immunotherapy, 4, 443, 10.2217/imt.12.28 · DOI
  35. Okada, 2011, Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma, J Clin Oncol, 29, 330, 10.1200/JCO.2010.30.7744 · DOI
  36. Costa, 2005, Two novel proteins recruited by synaptonemal complex protein 1 (SYCP1) are at the centre of meiosis, J Cell Sci, 118, 2755, 10.1242/jcs.02402 · DOI
  37. Lim, 2005, Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation, Int J Cancer, 116, 200, 10.1002/ijc.21007 · DOI
  38. Takenouchi, 2011, Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts, Clin Cancer Res, 17, 2819, 10.1158/1078-0432.CCR-10-2986 · DOI

Metadata

Authors
Taguchi, A., Taylor, A. D., Rodriguez, J., Çeliktaş, M., Liu, H., Ma, X., Zhang, Q., Wong, C.-H., Chin, A., Girard, L., Behrens, C., Lam, W. L., Lam, S., Minna, J. D., Wistuba, I. I., Gazdar, A. F., & Hanash, S. M.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Fred Hutch Cancer Center (US)
  • 1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • The University of Texas Southwestern Medical Center (US)
  • BC Cancer Agency (CA)
Corresponding author
Taguchi, Ayumu
ORCID
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2014-09-01
Volume
74
Issue
17
Pages
4694-4705
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
DOI
10.1158/0008-5472.can-13-3725
PMC
PMC4398029
OpenAlex
W2105545710
Cited by
53
References
1
Citations by year
2025: 3 · 2024: 1 · 2023: 8 · 2022: 11 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 9 · 2015: 1
FWCI
1.97
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P50CA070907, P30CA016672, P30CA015704)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
cancer-testis antigens, lung cancer, lung adenocarcinoma, squamous cell carcinoma, IL13RA2, testis-specific gene expression, tumor-specific antigens, cancer immunotherapy targets
MeSH terms
Antigens, Neoplasm, Cell Line, DNA-Binding Proteins, Multigene Family, Humans, Immunotherapy, Lung Neoplasms, Male, Nuclear Proteins, RNA, Messenger, Testis, Cell Line, Tumor, Receptors, Interleukin-13, Interleukin-13 Receptor alpha1 Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review